Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India-Reference-Cited by-同舟云学术

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India

Published:2021-11 Issue: Volume:Volume 13 Page:625-640
ISSN:1179-1314
Container-title:Breast Cancer: Targets and Therapy
language:en
Short-container-title:BCTT

Author:

Butani Dimple,Gupta Nidhi,Jyani Gaurav^ORCID,Bahuguna Pankaj,Kapoor Rakesh,Prinja Shankar^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference67 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Epidemiology of breast cancer in Indian women

3. A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery

4. Lurie RH, Anderson BO, Abraham J, et al. NCCN guidelines version 5.2020 breast cancer; 2020.

5. Standard treatment guidelines oncology. Ministry of health & family welfare Government of India 2.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer;Breast Cancer;2024-06-15

2. Simulating the impact of psychologist prescribing authority policies on mental health prescriber shortages.;Professional Psychology: Research and Practice;2024-04

3. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial;Integrative Cancer Therapies;2023-01